Literature DB >> 11479352

A 'fair innings' for efficiency in health services?

N Bosanquet1.   

Abstract

This paper reviews the severe visual focus problems of health economists-they have developed a one-sided fixation with equity issues, neglecting the efficiency agenda. The problems of meeting need are not just about access--they will vary with cost and supply. Economists in fact developed a more balanced agenda in the 1970s but have failed to follow it up. The paper defines the triple nationalisation of the National Health Service (NHS), and presents evidence that pluralism, using the purchaser/provider split, has become more efficient in long term care, home care and services for people with learning difficulties. Health economics has failed to explore options for using the dynamic forces of choice and competition for improving health services. The paper makes the case for a decision rule that "we should seek the process of health care service supply and development which maximises the delivery of high quality, lower cost user relevant services".

Entities:  

Keywords:  National Health Service

Mesh:

Year:  2001        PMID: 11479352      PMCID: PMC1733419          DOI: 10.1136/jme.27.4.228

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  4 in total

Review 1.  Equity and equality in health and health care.

Authors:  A J Culyer; A Wagstaff
Journal:  J Health Econ       Date:  1993-12       Impact factor: 3.883

2.  Reweighing heat: response to Culyer, van Doorslaer and Wagstaff.

Authors:  G Mooney; J Hall; C Donaldson; K Gerard
Journal:  J Health Econ       Date:  1992-08       Impact factor: 3.883

Review 3.  Utilisation as a measure of equity: weighing heat?

Authors:  G Mooney; J Hall; C Donaldson; K Gerard
Journal:  J Health Econ       Date:  1991       Impact factor: 3.883

Review 4.  Intergenerational equity: an exploration of the 'fair innings' argument.

Authors:  A Williams
Journal:  Health Econ       Date:  1997 Mar-Apr       Impact factor: 3.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.